Next Article in Journal
Quantitative Multiplex Real-Time Reverse Transcriptase–Polymerase Chain Reaction with Fluorescent Probe Detection of Killer Immunoglobulin-Like Receptors, KIR2DL4/3DL3
Previous Article in Journal
Trends in Hospitalization of Patients with Potentially Serious Diseases Evaluated at a Quick Diagnosis Clinic
Open AccessArticle

The Role of Fecal Calprotectin in Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth (SIBO)

1
Chair and Department of Dermatology, Venerology and Pediatric Dermatology, Medical University of Lublin, Staszica 16, 20-400 Lublin, Poland
2
Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13, 20-080 Lublin, Poland
*
Author to whom correspondence should be addressed.
Diagnostics 2020, 10(8), 587; https://doi.org/10.3390/diagnostics10080587
Received: 1 July 2020 / Revised: 1 August 2020 / Accepted: 10 August 2020 / Published: 13 August 2020
(This article belongs to the Section Diagnostic Microbiology and Infectious Disease)
Fecal calprotectin (FC) is a quick, cost-effective, and noninvasive test, which is used to diagnose patients with active inflammatory bowel diseases (IBD). Recent studies suggest the possible predictive role of FC in the diagnosis of small intestinal bacterial overgrowth (SIBO) in patients with systemic sclerosis (SSc). This study aimed to assess the predictive value of FC in SSc patients and its’ possible use as a SIBO marker. A total of 40 SSc patients and 39 healthy volunteers were enrolled in the study. All subjects completed questionnaires evaluating gastrointestinal symptoms, FC measurements, and lactulose hydrogen breath test (LHBT) assessing SIBO presence. After rifaximin treatment, patients with SIBO underwent the same diagnostic procedures. Significantly higher FC values were observed in the study group compared to controls (97 vs. 20 μg/g; p < 0.0001) and in SSc patients diagnosed with SIBO compared to SSc patients without SIBO (206 vs. 24 μg/g; p = 0.0010). FC turned out to be a sensitive (94.12%) and specific (73.68%) marker in the detection of SIBO in patients with SSc (AUC = 0.82, 95% CI = 0.66–0.93; p < 0.0001). Our study suggests the potential value of FC in SSc in detecting gastrointestinal impairment and its promising role as an additional diagnostic tool for SIBO. View Full-Text
Keywords: calprotectin; small intestinal bacterial overgrowth; SIBO; systemic sclerosis calprotectin; small intestinal bacterial overgrowth; SIBO; systemic sclerosis
Show Figures

Figure 1

MDPI and ACS Style

Polkowska-Pruszyńska, B.; Gerkowicz, A.; Rawicz-Pruszyński, K.; Krasowska, D. The Role of Fecal Calprotectin in Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth (SIBO). Diagnostics 2020, 10, 587. https://doi.org/10.3390/diagnostics10080587

AMA Style

Polkowska-Pruszyńska B, Gerkowicz A, Rawicz-Pruszyński K, Krasowska D. The Role of Fecal Calprotectin in Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth (SIBO). Diagnostics. 2020; 10(8):587. https://doi.org/10.3390/diagnostics10080587

Chicago/Turabian Style

Polkowska-Pruszyńska, Beata; Gerkowicz, Agnieszka; Rawicz-Pruszyński, Karol; Krasowska, Dorota. 2020. "The Role of Fecal Calprotectin in Patients with Systemic Sclerosis and Small Intestinal Bacterial Overgrowth (SIBO)" Diagnostics 10, no. 8: 587. https://doi.org/10.3390/diagnostics10080587

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop